Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc (AVDL)

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,886
  • Shares Outstanding, K 37,355
  • Annual Sales, $ 103,270 K
  • Annual Income, $ -95,300 K
  • 60-Month Beta 1.55
  • Price/Sales 1.20
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +153,792.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +68.50%
on 08/27/19
3.47 -2.88%
on 09/19/19
+1.29 (+62.02%)
since 08/20/19
3-Month
1.82 +85.16%
on 08/13/19
3.47 -2.88%
on 09/19/19
+0.58 (+20.79%)
since 06/20/19
52-Week
1.03 +227.18%
on 04/29/19
4.83 -30.23%
on 10/03/18
-1.13 (-25.11%)
since 09/20/18

Most Recent Stories

More News
Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

--Expresses Disappointment with Current Board's Actions Following Stockholder Vote Results Calling for Change and its Continued Refusal to Address the Real Issues Facing Progenics

OPNT : 16.48 (+3.00%)
AVDL : 3.37 (+1.81%)
PGNX : 5.24 (-2.06%)
YMAB : 30.95 (-1.02%)
Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director of the Sleep-Wake Disorders Center at the Montefiore Medical...

AVDL : 3.37 (+1.81%)
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that its Chief Executive Officer, Greg Divis,...

AVDL : 3.37 (+1.81%)
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones....

AVDL : 3.37 (+1.81%)
JAZZ : 129.21 (-0.03%)
NVS : 87.07 (+0.83%)
TEVA : 7.45 (-1.06%)
Avadel: 2Q Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Friday reported a loss of $8.6 million in its second quarter.

AVDL : 3.37 (+1.81%)
Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update

-- Better-than-expected Hospital Product revenue improves liquidity position

AVDL : 3.37 (+1.81%)
Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User...

AVDL : 3.37 (+1.81%)
Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointments of Courtney Wells as Vice-President, Clinical Operations and David Seiden,...

AVDL : 3.37 (+1.81%)
Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday,...

AVDL : 3.37 (+1.81%)
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

AVDL : 3.37 (+1.81%)
JAZZ : 129.21 (-0.03%)
NVS : 87.07 (+0.83%)
TEVA : 7.45 (-1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 3.53
1st Resistance Point 3.45
Last Price 3.37
1st Support Level 3.29
2nd Support Level 3.21

See More

52-Week High 4.83
Fibonacci 61.8% 3.38
Last Price 3.37
Fibonacci 50% 2.93
Fibonacci 38.2% 2.48
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar